R. O'Connell

发表

Rates and predictors of risk of stroke and its subtypes in diabetes: a prospective observational study

G. Hankey, A. Keech, D. Hunt, 2012, Journal of Neurology, Neurosurgery & Psychiatry.

Frequency of recurrent ST-elevation myocardial infarction after fibrinolytic therapy in a different territory as a manifestation of multiple unstable coronary arterial plaques.

H. White, R. Simes, Philip Aylward, 2006, The American journal of cardiology.

Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes.

A. Keech, P. Barter, A. Jenkins, 2012, The Journal of clinical endocrinology and metabolism.

Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes

A. Keech, M. Taskinen, G. Watts, 2021, Scientific Reports.

The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study

V. Gebski, A. Keech, R. Ma, 2021, Diabetes & vascular disease research.

Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: a Fenofibrate Intervention and Event Lowering in Diabetes Sub-study.

A. Keech, A. Jenkins, A. Januszewski, 2020, Diabetes research and clinical practice.

HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes

V. Gebski, A. Keech, M. Taskinen, 2014, Diabetes Care.

The Index of Microcirculatory Resistance Predicts Myocardial Infarction Related to Percutaneous Coronary Intervention

A. Keech, L. Kritharides, A. Yong, 2012, Circulation. Cardiovascular interventions.

Risk of mortality after acute myocardial infarction: Performance of model updating methods for application in different geographical regions

H. Malcolm Hudson, Rachel L. O'Connell, H. Hudson, 2009, Comput. Stat. Data Anal..

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

V. Gebski, A. Keech, P. Glasziou, 2011, Diabetologia.

A Novel Method to Adjust Efficacy Estimates for Uptake of Other Active Treatments in Long-Term Clinical Trials

A. Keech, K. Byth, J. Simes, 2010, PloS one.

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

John Fuller, Luigi Tavazzi, John Wikstrand, 2019, The Lancet.

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials

Barry J. Davis, R. Collins, A. Keech, 2015, The Lancet.

Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study.

A. Keech, M. Taskinen, P. Barter, 2017, Clinical Chemistry.

Single index of multimorbidity did not predict multiple outcomes.

C. D’Este, J. Byles, C. Treloar, 2005, Journal of clinical epidemiology.

Plasma total bilirubin levels predict amputation events in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

A. Keech, M. Vanhala, D. Sullivan, 2013, Diabetologia.

Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial.

R. Califf, R. Diaz, I. Marschner, 2010, American heart journal.

Variations in the use of emergency PCI for the treatment of re-infarction following intravenous fibrinolytic therapy: impact on outcomes in HERO-2.

H. White, R. Simes, P. Aylward, 2006, European heart journal.

Stratified additive Poisson models: Computational methods and applications in clinical epidemiology

Ian C. Marschner, Alexandra C. Gillett, Rachel L. O'Connell, 2012, Comput. Stat. Data Anal..

Vitamin D supplementation and risk of falling: outcomes from the randomized, placebo‐controlled D‐Health Trial

D. English, A. Venn, D. Whiteman, 2021, Journal of cachexia, sarcopenia and muscle.

Abstract 17705: Overestimation by Common Cardiovascular Risk Scores Amongst Primary Prevention Patients in the Cholesterol Treatment Trialists’ Collaboration (CTTC) Database

A. Keech, R. O'Connell, J. Fulcher, 2015 .

Long-term glycaemic variability and vascular complications in Type 2 diabetes: Post-hoc analysis of the FIELD Study.

A. Keech, S. Colagiuri, A. Jenkins, 2020, The Journal of clinical endocrinology and metabolism.

Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study

A. Keech, M. Taskinen, P. Barter, 2015, Diabetologia.

The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study

A. Keech, M. Taskinen, P. Barter, 2015, Diabetologia.

Making sense of trial results: outcomes and estimation

V. Gebski, A. Keech, R. O'Connell, 2004, The Medical journal of Australia.

Eff ect of fenofi brate on the need for laser treatment for diabetic retinopathy ( FIELD study ) : a randomised controlled trial

P. Mitchell, A. Keech, M. Taskinen, 2007 .

Uric acid predicts long‐term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study

V. Gebski, A. Keech, I. Marschner, 2020, Diabetes, obesity & metabolism.

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial

P. Mitchell, A. Keech, M. Taskinen, 2007, The Lancet.